0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Treatment response as a biomarker

Session 1: Biomarkers in migraine

Mikko Kallela

Assistant Professor & Neurologist, Department of Neurology at Helsinki University Hospital & Helsinki Headache Center, Finland

Previous

Biomarkers with focus on genetics

Next

Epidemiology

You Might Also Like

Related Embedded Video Item Thumbnail Epidemiology
Related Embedded Video Item Thumbnail Misconceptions on migraine and treatments - social media, Google, etc.
Related Embedded Video Item Thumbnail Migraine in elderly
Related Embedded Video Item Thumbnail Patient FAQs & demands and how to address
Related Embedded Video Item Thumbnail New EHF guideline on the use of MAb’s for migraine prevention

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128